|
1
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Q, Zeng L, Chen Y, Lian G, Qian C,
Chen S, Li J and Huang K: Pancreatic cancer epidemiology,
detection, and management. Gastroenterol Res Pract. 2016:8962321.
2016. View Article : Google Scholar
|
|
3
|
Zeng S, Pöttler M, Lan B, Grützmann R,
Pilarsky C and Yang H: Chemoresistance in pancreatic cancer. Int J
Mol Sci. 20:E45042019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Manning BD and Toker A: AKT/PKB signaling:
Navigating the network. Cell. 169:381–405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arlt A, Müerköster SS and Schäfer H:
Targeting apoptosis pathways in pancreatic cancer. Cancer Lett.
332:346–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang XJ and Jia SS: Fisetin inhibits
laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2
signaling pathways. Biomed Pharmacother. 83:1164–1174. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yap TA, Yan L, Patnaik A, Fearen I, Olmos
D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, et
al: First-in-man clinical trial of the oral pan-AKT inhibitor
MK-2206 in patients with advanced solid tumors. J Clin Oncol.
29:4688–4701. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirai H, Sootome H, Nakatsuru Y, Miyama K,
Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS and
Kotani H: MK-2206, an allosteric Akt inhibitor, enhances antitumor
efficacy by standard chemotherapeutic agents or molecular targeted
drugs in vitro and in vivo. Mol Cancer Ther. 9:1956–1967. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin YH, Chen BYH, Lai WT, Wu SF, Guh JH,
Cheng AL and Hsu LC: The Akt inhibitor MK-2206 enhances the
cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer
cells. Naunyn Schmiedebergs Arch Pharmacol. 388:19–31. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arora S, Bhardwaj A, Singh S, Srivastava
SK, McClellan S, Nirodi CS, Piazza GA, Grizzle WE, Owen LB and
Singh AP: An undesired effect of chemotherapy: Gemcitabine promotes
pancreatic cancer cell invasiveness through reactive oxygen
species-dependent, nuclear factor κB- and hypoxia-inducible factor
1α-mediated up-regulation of CXCR4. J Biol Chem. 288:21197–21207.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okuzumi T, Fiedler D, Zhang C, Gray DC,
Aizenstein B, Hoffman R and Shokat KM: Inhibitor hijacking of Akt
activation. Nat Chem Biol. 5:484–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin P, Wong CC, Mei S, He X, Qian Y and
Sun L: MK-2206 co-treatment with 5-fluorouracil or doxorubicin
enhances chemosensitivity and apoptosis in gastric cancer by
attenuation of Akt phosphorylation. OncoTargets Ther. 9:4387–4396.
2016. View Article : Google Scholar
|
|
15
|
Li Z, Yan S, Attayan N, Ramalingam S and
Thiele CJ: Combination of an allosteric Akt Inhibitor MK-2206 with
etoposide or rapamycin enhances the antitumor growth effect in
neuroblastoma. Clin Cancer Res. 18:3603–3615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Burke JF, Schlosser L, Harrison AD,
Kunnimalaiyaan M and Chen H: MK-2206 causes growth suppression and
reduces neuroendocrine tumor marker production in medullary thyroid
cancer through Akt inhibition. Ann Surg Oncol. 20:3862–3868. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amrutkar M and Gladhaug IP: Pancreatic
cancer chemoresistance to gemcitabine. Cancers. 9:157–180. 2017.
View Article : Google Scholar
|
|
19
|
Molife LR, Yan L, Vitfell-Rasmussen J,
Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E,
Siu LL, et al: Phase 1 trial of the oral AKT inhibitor MK-2206 plus
carboplatin/paclitaxel, docetaxel, or erlotinib in patients with
advanced solid tumors. J Hematol Oncol. 7:12014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lara PN Jr, Longmate J, Mack PC, Kelly K,
Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL and
Gandara DR: Phase II study of the AKT inhibitor MK-2206 plus
erlotinib in patients with advanced non-small cell lung cancer who
previously progressed on erlotinib. Clin Cancer Res. 21:4321–4326.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ramanathan RK, McDonough SL, Kennecke HF,
Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM and
Blanke CD: Phase 2 study of MK-2206, an allosteric inhibitor of
AKT, as second-line therapy for advanced gastric and
gastroesophageal junction cancer: A SWOG cooperative group trial (S
1005). Cancer. 121:2193–2197. 2015. View Article : Google Scholar : PubMed/NCBI
|
